Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed soft tissue angiosarcoma or lymphangiosarcoma~  * Locally advanced or metastatic disease~ * Unresectable disease~* Angiosarcomas in previously irradiated areas allowed provided disease is clearly progressive~* Measurable disease~* No Kaposi's sarcoma~PATIENT CHARACTERISTICS:~Age~* 18 to 70~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count \> 1,500/mm\^3~* Platelet count \> 100,000/mm\^3~Hepatic~* Bilirubin \< 3 times upper limit of normal (ULN)~* SGOT and SGPT \< 2.5 times ULN~* No severe liver failure~Renal~* Creatinine clearance \> 60 mL/min~* No severe kidney failure~Cardiovascular~* LVEF ≥ 50%~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No weight loss ≥ 20% of body weight prior to illness~* Patient must be amenable to receiving care during the day~* No HIV positivity~* No clinical neuropathy~* No known allergy to study drug or to any of its components (e.g., Cremophor EL)~* No other progressive malignant tumor~* No chronic illness (somatic or psychiatric) that would preclude study compliance and follow-up~* No psychological, geographical, or social reason that would preclude study follow-up~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No more than 2 prior courses of chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~Surgery~* Not specified~Other~* No other concurrent anticancer therapy~* No concurrent participation in another therapeutic investigational study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Paclitaxel (Type: EXPERIMENTAL): Paclitaxel 80 mg/m² Day 1, Day 8 and Day 15. No treatment on Day 22.~1 cycle = 28 days.~Treatment duration: 6 cycles (=6 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).